Core Insights - Processa Pharmaceuticals, Inc. announced the acceptance of three abstracts for the 2025 ASCO Annual Meeting, showcasing its Next Generation Cancer (NGC) drug candidates, including PCS6422 and PCS11T [1][6] Abstract Summaries - The first abstract discusses the safety and efficacy of Eniluracil + Capecitabine (6422 + Cap) in a Phase 1b trial, highlighting its improved safety profile and anti-tumor activity compared to standard capecitabine [3][4] - The second abstract outlines a Project Optimus-aligned approach for the preclinical study of PCS11T, a tumor-targeted pro-drug of SN-38, aimed at increasing drug concentration in tumors while minimizing systemic toxicity [4][5] - The third abstract presents an overview of an ongoing Phase 2 adaptive design trial evaluating the safety and efficacy of PCS6422 combined with capecitabine in patients with advanced or metastatic breast cancer, focusing on optimal dosing regimens and personalized medicine [9]